SavedAdd your journal

Journals / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 9

Surgical treatment of secondary hyperparathyroidism

Erdem KARADENİZ
Ayetullah TEMİZ
Yusuf TANRİKULU
Pages
1792–1797
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Persistent hyperparathyroidism wasseen in 2 patients who underwent subtotal parathyroidectomy and 1 patient who underwent adenoma excision.Conclusion: Today, the treatment of sHPT is still the best treatment option, and as a treatment, subtotal parathyroidectomy and totalparathyroidectomy + parathyroid autoimplantation surgery should be preferred.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Initial treatment of secondary hyperparathyroidism (sHPT), often seen as a result of end-stage renal failure, is medicaltreatment.
📊
Key Findings & Data:The aim of this study is to evaluate the diagnosis and treatment of patientswho underwent sHPT.Material and Methods: Twenty-one patients who were operated for sHPT were included in the study.
💡
Conclusion & Impact:Persistent hyperparathyroidism wasseen in 2 patients who underwent subtotal parathyroidectomy and 1 patient who underwent adenoma excision.Conclusion: Today, the treatment of sHPT is still the best treatment option, and as a treatment, subtotal parathyroidectomy and totalparathyroidectomy + parathyroid autoimplantation surgery should be preferred.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Initial treatment of secondary hyperparathyroidism (sHPT), often seen as a result of end-stage renal failure, is medicaltreatment. Treatment-resistant patients require surgery. The aim of this study is to evaluate the diagnosis and treatment of patientswho underwent sHPT.Material and Methods: Twenty-one patients who were operated for sHPT were included in the study. The demographic data of thepatients and correlation of imaging results with correct localization and pathological diagnosis were evaluated.Results: The mean age of the patients was 45.80±1.10. While the number of patients with growth in a parathyroid gland was 7 (32%),the number of patients with multiple glands was 8 (39%). According to scintigraphy evaluation, the same values were 4 (19%) and 12(57%) patients. 7 (34%) patients were underwent adenoma excision, 11 (52%) patients were underwent subtotal parathyroidectomyand 3 (14%) patients were underwent total parathyroidectomy + parathyroid auto-implantation. Persistent hyperparathyroidism wasseen in 2 patients who underwent subtotal parathyroidectomy and 1 patient who underwent adenoma excision.Conclusion: Today, the treatment of sHPT is still the best treatment option, and as a treatment, subtotal parathyroidectomy and totalparathyroidectomy + parathyroid autoimplantation surgery should be preferred.

🔖

Cite This Article

KARADENİZ, E., TEMİZ, A., TANRİKULU, Y. (2022). Surgical treatment of secondary hyperparathyroidism. Annals of Medical Research, Cilt: 26 - Sayı: 9, 1792–1797. https://ajindex.com/articles/447341

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992;38:62-7
  2. Hacıyanlı M, Atahan K. Sekonder hiperparatiroidide cerrahi tedavi. Endokrinolojide Diyalog 2010;7:156-61
  3. Toçoğlu GA, Sipahi S, Tamer A. Sekonder hiperparatiroidi nedeniyle opere olan hastalar ile medikal tedavi alan hastalar arasindaki maliyet analizi. Turk Neph Dial Transpl 2015;24:82-7
  4. Sancho JJ, Sitges-Serra A. Metabolic complications of secondary hyperparathyroidism. In: Clark OH, Duh QY, Kebebew E, eds. Textbook of Endocrine Surgery, Philadelphia, Elsevier Inc; 2005. p. 502-9
  5. Liang Y, Sun Y, Ren L, et al. Short-term efficacy of surgical treatment of secondary hyperparathyroidism. Eur Rev Med Pharmacol Sci 2015;19:3904-9
  6. Uhlig K, Berns JS, Kestenbaum B,et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline forthe Diagnosis, Evaluation, and Treatment of CKDMineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010;55:773-99
  7. Dumasius V, Angelos P. Parathyroid surgery in renal failure patients. Otolaryngol Clin North Am 2010;43:433-40
  8. Ekici Y, Pehlivan S, Karakayalı FY, ve ark. Sekonder hiperparatiroidizm tedavisinde subtotal paratiroidektominin etkinliği: Bir merkezin sonuçları. Ulusal Cerrahi Dergisi 2007;23:41-5
  9. Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014;24:CD006254
  10. Uludağ M. Kronik Böbrek Hastalıklı Hastalarda Sekonder Hiperparatiroidizm: Tanı, Medikal ve Cerrahi Tedavi. Şişli Etfal Hastanesi Tıp Bülteni 2016;50:256-72
  11. Pitt SC, Sippel RS, Chen H. Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am 2009;89:1227-39
  12. Madorin C, Owen RP, Fraser WD, et al. The surgical management of renal hyperparathyroidism. Eur Arch Otorhinolaryngol 2012;269:1565-76
  13. Xu D, Yin Y, Hou L, et al. Surgical management of secondary hyperparathyroidism: how to effectively reduce recurrence at the time of primary surgery. J Endocrinol Invest 2016;39:509-14
  14. Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25- dihydroxyvitamin D3 receptor density is as¬sociated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43
  15. Gogusev J, Duchambon P, Hory B,et al. De¬pressed expression of calcium receptor in para-thyroid gland tissue of patients with hyperpar-athyroidis